surmount trials tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial SURMOUNT-1: Tirzepatide Drastically Reduces Weight – SURPASS-CVOT Published: Large Trial Confirms

Our experienced healthcare provider can help determine if tirzepatide is the right option for you

The kits will be available for a limited time

Emerging evidence highlighted that GLP-1 RAs and DPP-4i profoundly affect the gastrointestinal motor system, which may influence the bowel cleaning quality

Exciting new developments in the world of metabolic health

These state signals may alter subjective hedonic evaluation (liking) and motivational drive (wanting) without necessarily affecting basic gustatory discrimination

Your body should respond by naturally lowering hunger and cravings and automatically moving toward a healthy weight